Fairfax Financial Holdings Limited (OTCMKTS:FRFHF – Free Report) – Investment analysts at National Bank Financial raised their Q1 2025 earnings per share (EPS) estimates for shares of Fairfax Financial in a research report issued on Thursday, October 31st. National Bank Financial analyst J. Gloyn now anticipates that the financial services provider will earn $41.53 per share for the quarter, up from their previous forecast of $40.52. The consensus estimate for Fairfax Financial’s current full-year earnings is $149.57 per share. National Bank Financial also issued estimates for Fairfax Financial’s Q2 2025 earnings at $38.39 EPS, Q3 2025 earnings at $37.24 EPS, FY2025 earnings at $160.83 EPS and FY2026 earnings at $167.32 EPS.
Separately, Royal Bank of Canada boosted their price target on Fairfax Financial from $1,425.00 to $1,500.00 and gave the company an “outperform” rating in a research note on Monday.
Fairfax Financial Stock Performance
FRFHF opened at $1,304.30 on Monday. The firm’s 50-day moving average price is $1,240.40 and its 200-day moving average price is $1,166.88. The company has a market cap of $30.29 billion, a P/E ratio of 7.98 and a beta of 0.79. Fairfax Financial has a 52-week low of $868.00 and a 52-week high of $1,356.00. The company has a quick ratio of 4.09, a current ratio of 4.09 and a debt-to-equity ratio of 0.42.
Fairfax Financial Company Profile
Fairfax Financial Holdings Limited, through its subsidiaries, provides property and casualty insurance and reinsurance, and investment management services in the United States, Canada, Asia, and internationally. The company operates through Property and Casualty Insurance and Reinsurance, Life insurance and Run-off, and Non-Insurance Companies segments.
Featured Stories
- Five stocks we like better than Fairfax Financial
- How Can Investors Benefit From After-Hours Trading
- Intel: Is Now the Time to Be Brave?Â
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- How to Buy Cheap Stocks Step by Step
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Fairfax Financial Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fairfax Financial and related companies with MarketBeat.com's FREE daily email newsletter.